See more : Stadler Rail AG (0A0C.L) Income Statement Analysis – Financial Results
Complete financial analysis of Mizuho Medy Co.,Ltd. (4595.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mizuho Medy Co.,Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Nuran Wireless Inc. (NRRWF) Income Statement Analysis – Financial Results
- Hank Payments Corp. (HANK.V) Income Statement Analysis – Financial Results
- Saturn Oil & Gas Inc. (OILSF) Income Statement Analysis – Financial Results
- QPR Software Oyj (QPR1V.HE) Income Statement Analysis – Financial Results
- Promotora y Operadora de Infraestructura, S. A. B. de C. V. (PINFRAL.MX) Income Statement Analysis – Financial Results
Mizuho Medy Co.,Ltd. (4595.T)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.mizuho-m.co.jp
About Mizuho Medy Co.,Ltd.
Mizuho Medy Co.,Ltd. researches and develops, manufactures, and sells in-vitro diagnostic products and related scientific and technical information services primarily in Japan. The company provides immunoassay test products, such as influenza virus kits; RS virus and human metapneumovirus antigen test kits; streptococcus pneumoniae antigen and legionella antigen test kits; mycoplasma pneumoniae antigen test kits; adenovirus antigen test kits; rotavirus and adenovirus antigen test kits; norovirus antigen test kits; group a streptococcal antigen test kits; pregnancy test kits; ovulation test kits; and fecal occult blood test kits. It also offers gene analysis instrument; SARS-CoV-2 detection kits; and mycoplasma pneumoniae nucleic acid kits. In addition, the company engages in import and export activities. It also operates in the United States, Belgium, Finland, Netherlands, Taiwan, Thailand, etc. The company was incorporated in 1977 and is headquartered in Tosu, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.99B | 17.58B | 12.89B | 4.20B | 6.43B | 6.43B | 5.62B | 4.96B | 4.08B | 4.00B | 3.25B |
| Cost of Revenue | 2.92B | 3.48B | 3.23B | 1.44B | 2.09B | 2.10B | 1.96B | 1.77B | 1.42B | 1.35B | 1.15B |
| Gross Profit | 8.07B | 14.10B | 9.65B | 2.76B | 4.34B | 4.33B | 3.66B | 3.19B | 2.66B | 2.65B | 2.10B |
| Gross Profit Ratio | 73.47% | 80.20% | 74.90% | 65.63% | 67.52% | 67.34% | 65.06% | 64.30% | 65.16% | 66.27% | 64.75% |
| Research & Development | 669.08M | 605.47M | 592.32M | 509.46M | 461.92M | 460.66M | 386.34M | 357.00M | 306.70M | 285.91M | 258.00M |
| General & Administrative | 419.12M | 575.45M | 503.88M | 246.91M | 310.07M | 290.36M | 267.82M | 356.91M | 344.79M | 279.79M | 58.00M |
| Selling & Marketing | 1.79B | 0.00 | 224.34M | 384.57M | 1.05B | 1.04B | 991.90M | 1.00B | 727.98M | 777.74M | 576.00M |
| SG&A | 2.20B | 575.45M | 728.21M | 631.48M | 1.36B | 1.34B | 1.26B | 1.36B | 1.07B | 1.06B | 1.63B |
| Other Expenses | 48.33M | 7.21M | 674.00K | 831.00K | 1.55M | -8.87M | 1.34M | -2.20M | 2.33M | 1.86M | 0.00 |
| Operating Expenses | 2.92B | 3.00B | 2.95B | 2.34B | 3.23B | 3.11B | 2.81B | 2.34B | 1.97B | 1.91B | 1.89B |
| Cost & Expenses | 5.84B | 6.48B | 6.19B | 3.79B | 5.32B | 5.20B | 4.77B | 4.11B | 3.40B | 3.26B | 3.04B |
| Interest Income | 41.44M | 9.47M | 1.77M | 29.00K | 26.00K | 24.00K | 22.00K | 29.00K | 34.00K | 17.00K | 7.00M |
| Interest Expense | 0.00 | 0.00 | 1.24M | 2.09M | 1.89M | 1.13M | 1.47M | 3.02M | 4.85M | 6.25M | 0.00 |
| Depreciation & Amortization | 195.49M | 157.78M | 172.60M | 193.85M | 167.26M | 96.71M | 77.11M | 65.05M | 52.28M | 49.57M | 13.00M |
| EBITDA | 5.35B | 11.23B | 7.00B | 611.11M | 1.34B | 1.30B | 929.71M | 592.79M | 426.88M | 515.16M | 213.00M |
| EBITDA Ratio | 48.66% | 64.03% | 53.35% | 14.51% | 19.90% | 20.38% | 16.53% | 18.51% | 17.81% | 19.78% | 6.56% |
| Operating Income | 5.15B | 11.10B | 6.70B | 416.22M | 1.11B | 1.22B | 850.44M | 529.44M | 388.33M | 465.09M | 200.00M |
| Operating Income Ratio | 46.88% | 63.16% | 51.98% | 9.90% | 17.29% | 19.00% | 15.12% | 10.67% | 9.51% | 11.63% | 6.16% |
| Total Other Income/Expenses | 140.49M | -33.32M | 126.02M | -1.05M | 59.71M | -8.92M | 686.00K | -4.27M | -18.59M | -5.75M | 5.00M |
| Income Before Tax | 5.29B | 11.07B | 6.82B | 415.17M | 1.17B | 1.21B | 851.13M | 524.73M | 369.75M | 459.34M | 205.00M |
| Income Before Tax Ratio | 48.16% | 62.97% | 52.96% | 9.88% | 18.22% | 18.86% | 15.13% | 10.57% | 9.06% | 11.49% | 6.31% |
| Income Tax Expense | 1.52B | 3.23B | 2.01B | 108.83M | 296.44M | 292.59M | 191.08M | 129.53M | 112.15M | 142.04M | 66.00M |
| Net Income | 3.77B | 7.84B | 4.82B | 306.35M | 874.34M | 919.21M | 660.05M | 395.21M | 257.60M | 317.30M | 139.00M |
| Net Income Ratio | 34.34% | 44.58% | 37.38% | 7.29% | 13.60% | 14.31% | 11.74% | 7.96% | 6.31% | 7.94% | 4.28% |
| EPS | 396.27 | 822.94 | 505.72 | 32.16 | 91.80 | 96.51 | 69.30 | 41.49 | 30.31 | 37.51 | 65.72 |
| EPS Diluted | 396.27 | 822.94 | 505.72 | 32.16 | 91.80 | 96.51 | 69.30 | 41.49 | 30.31 | 37.51 | 65.72 |
| Weighted Avg Shares Out | 9.52M | 9.52M | 9.52M | 9.52M | 9.52M | 9.52M | 9.52M | 9.53M | 8.50M | 8.46M | 2.12M |
| Weighted Avg Shares Out (Dil) | 9.52M | 9.52M | 9.52M | 9.52M | 9.52M | 9.52M | 9.52M | 9.53M | 8.50M | 8.46M | 2.12M |
Source: https://incomestatements.info
Category: Stock Reports